drugset / Trial / NCT00648336

Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg

NCT00648336

Phase 1 Completed 60 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's mercaptopurine 50 mg tablets to Gate's Purinethol® 50 mg tablets following a single, oral 50 mg (1 x 50 mg) dose administered under fasting conditions.

Timeline

Start
2003-11
Primary completion
2003-12
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MERCAPTOPURINE ANHYDROUS Small molecule 50 mg Oral

Indications

No indication recorded.